Stance on Information Disclosure

Basic Stance on Information Disclosure

In accordance with the policy stated in our Declaration of Conduct, we at Sumitomo Pharma proactively disclose information to the public and, under the recognition of the importance of transparency in earning society's trust, we work to disclose our corporate information in a timely, appropriate, and fair manner to our stakeholders.

Standards for Information Disclosure

  • In regard to information required to be disclosed by the Timely Disclosure Rules of the Tokyo Stock Exchange (TSE), we disclose such information in accordance with those rules.
  • In regard to information not required to be disclosed by the rules of TSE, we will work to proactively disclose information that may be requested by stakeholders or useful for stakeholders to understand Sumitomo Pharma.

Process of Disclosure

Pursuant to the Information Disclosure Code that prescribes such matters as standards and procedures for disclosing information, the Company discloses corporate information in a timely, appropriate and fair manner. The system for timely disclosure of information is prescribed as follows. Please also refer to the figure of "Internal system for disclosure of corporate information."

(1) Disclosure of Decisions

The decisions, set forth in the Timely Disclosure Rules, are immediately disclosed as soon as such decisions are made by the Board of Directors or other decision making bodies (including decision making bodies of subsidiaries). The details of the matters to be disclosed are determined by Vice President, Head of Corporate Governance upon discussion with leaders of other relevant departments.

(2) Disclosure of Facts Which Occurred

The facts which occurred, set forth in the Timely Disclosure Rules, are promptly disclosed after the occurrence of the said facts. The details of the matters to be disclosed are determined by Vice President, Head of Corporate Governance upon discussion with leaders of other relevant departments.

(3) Disclosure of Account Settlement Information

The account settlement information, set forth in the Timely Disclosure Rules, is immediately disclosed after the resolution of the Board of Directors. The details of the matters to be disclosed are discussed by Vice President, Head of Corporate Governance, Vice President, Head of Global Corporate Strategy, and Vice President, Head of Global Finance. The details of the matters to be disclosed relating to financial result summaries and other related matters are determined by Vice President, Head of Corporate Governance and revision of financial forecasts and dividend forecasts and other related matters are determined by Vice President, Head of Global Corporate Strategy, respectively.

(4) Information Other Than Information to be Timely Disclosed

The Company discloses information necessary for stakeholders to correctly understand the Company in principle. The necessity of disclosure and the details and time of disclosure are determined by Vice President, Head of Corporate Governance upon discussion with leaders of other relevant departments.

■ Internal system for disclosure of corporate information

Internal system for disclosure of corporate information

Methods of Disclosure

  • Sumitomo Pharma discloses information through the TSE's Timely Disclosure Network (TDnet) and press releases (distributing material to mass media, press conferences, etc.). Disclosed material is also posted promptly on our corporate website.
  • In regard to information required to be disclosed by the Timely Disclosure Rules of the TSE, disclosure by other methods will be made only after disclosure on TDnet.

Material Non-public Information

  • Sumitomo Pharma shall not disclose material non-public information to shareholders, investors, etc.
  • In the event that we have done so in the course of our business without being aware that such information was material and non-public, we will disclose the same via the TDnet and our corporate website immediately after such disclosure has come to light.

Quiet Period

In order to prevent financial information leakage and ensure fairness in the disclosure of information, the period from the day following the end of each quarter through to the announcement of the financial results of such quarter is designated as "quiet period". During the quiet period, Sumitomo Pharma shall refrain from giving any comments or answers related to the financial results other than information disclosed prior to the quiet period. However, if a significant change to our previously announced financial forecast occurs during the quiet period, we shall disclose such information according to the Timely Disclosure Rules. Even during the quiet period, we will answer questions within the bounds of information disclosed before the quiet period, or information not related to the financial results.